Form D · Biotechnology
AgeX Therapeutics, Inc.
Alameda, CA · CIK 0001708599
Offering snapshot reported Mar 22, 2019 · SEC filing
- Reported sold
- $4.5M Offering amount: $5M
- Investors reported
- 17 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Mar 11, 2019 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Mar 22, 2019 | Initial | $4,500,000 | No comparison | 17 | SEC filing |
| Aug 27, 2018 | Initial | $200,000 | No comparison | 1 | SEC filing |
| Jun 21, 2018 | Initial | $5,000,000 | No comparison | 1 | SEC filing |
| Jan 31, 2018 | Initial | $462,500 | No comparison | 20 | SEC filing |
| Jul 10, 2017 | Initial | $8,850,000 | No comparison | 18 | SEC filing |
Offering details
- Securities
- Equity, Security to be acquired
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-335521
Source: Form D, filed Mar 22, 2019. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Gregory Bailey | Director |
| Not Applicable Bio Time, Inc. | Promoter |
| Annalisa Jenkins | Director |
| Alfred D. Kingsley | Director, Executive |
| John F. Mauldin | Director |
| Michael H. Mulroy | Director |
| Russell Skibsted | Executive |
| Michael D. West | Director, Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
1010 Atlantic Avenue Suite 102
Alameda, CA, 94501
Alameda, CA, 94501